Introduction: The emergence of drug-resistant influenza virus strains highlights the need for
new antiviral therapeutics to combat future pandemic outbreaks as well as continuing …

As resistance of influenza viruses to antiviral agents continues to evolve, new issues arise
concerning appropriate therapy and novel therapeutic means that target influenza infections …

The emergence of the 2009 H1N1 pandemic influenza A virus, as well as constant antigenic
drift of seasonal influenza, underscores the remarkable versatility of this virus in adapting to …

The influenza virus causes one of the most prevalent and lethal infectious viral diseases of
the respiratory system; the disease progression varies from acute self-limiting mild fever to …

Prevention and treatment of influenza virus infection is an ongoing unmet medical need.
Each year, thousands of deaths and millions of hospitalizations are attributed to influenza …

Influenza viruses are a major threat to human health globally. In addition to further improving
vaccine prophylaxis, disease management through antiviral therapeutics constitutes an …

Highlights•The existing influenza drugs suffer from variable efficacy and risk of
resistance.•Several new inhibitors of diverse viral targets are in clinical trials.•Broadly …

Influenza A virus is the major cause of seasonal or pandemic flu worldwide. Two main
treatment strategies–vaccination and small molecule anti-influenza drugs are currently …

Introduction: Influenza antiviral high-throughput screens have been extensive, and yet no
approved influenza antivirals have been identified through high-throughput screening. This …

The influenza A basic polymerase protein 2 (PB2) functions as part of a heterotrimer to
replicate the viral RNA genome. To investigate novel PB2 antiviral target sites, this work …